Zacks13d agobearish
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock FallsOCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
226last 24h
1319last 7d
227● bullish (7d)
148● bearish (7d)
205publishers
Zacks106d agobearish
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookOcugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.